WALTHAM, Mass.–(BUSINESS WIRE)– #ACR2026–Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.
WALTHAM, Mass.–(BUSINESS WIRE)– #ACR2026–Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.